Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer
27 Setembro 2023 - 10:00AM
Business Wire
Veracyte, Inc. (Nasdaq: VCYT) today announced that Phillip G.
Febbo, M.D., will join the company on October 2 as chief scientific
officer and chief medical officer. Dr. Febbo, a distinguished
industry and academic leader, will lead Veracyte’s global team of
research and development, medical affairs, clinical affairs,
quality, regulatory affairs, and lab director professionals to help
advance novel tests that address important unmet patient-care needs
in cancer. He will report to Marc Stapley, Veracyte’s chief
executive officer.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230927846710/en/
Veracyte Names Phillip G. Febbo, M.D., as
Chief Scientific Officer and Chief Medical Officer (Photo: Business
Wire)
“Phil is an exceptional leader with a strong track record of
driving successful commercialization of molecular tests through
evidence development, guideline inclusion and key opinion leader
support,” said Mr. Stapley. “His experience and expertise will be
critical to further enhancing our ability to serve our customers
and, ultimately, to transforming cancer care for patients all over
the world.”
Dr. Febbo has more than 25 years of experience across academia
and industry. He most recently served as chief medical officer for
Illumina where he built the medical team and led the successful
strategy to engage clinical customers. Prior to that, he was chief
medical officer for Genomic Health, where he oversaw the
development and expansion of the company’s test portfolio,
including the evidence demonstrating clinical validity and clinical
utility in order to drive reimbursement. Before Genomic Health, Dr.
Febbo was a professor of medicine and urology at the University of
California, San Francisco Medical Center, and prior to that he was
an associate professor of medicine and molecular genetics and
microbiology at Duke University School of Medicine. He currently
serves on the board of the Reagan Udall Foundation for the U.S.
Food and Drug Administration (FDA). Dr. Febbo holds a B.A. in
Biology from Dartmouth College and earned his M.D. from the
University of California, San Francisco. He completed his internal
medicine residency at Brigham and Women's Hospital and his medical
oncology fellowship at the Dana Farber Cancer Institute.
“Cancer mortality rates have started to improve due to better
detection and management. Veracyte has distinguished itself with
its high-performing tests that are helping physicians use
underlying biology of an individual’s cancer to make personalized
management decisions that improve patient outcomes and healthcare
efficiencies,” said Dr. Febbo. “I am thrilled to join the company’s
talented team and to help advance the future of insight-driven
care.”
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose
vision is to transform cancer care for patients all over the world.
We empower clinicians with the high-value insights they need to
guide and assure patients at pivotal moments in the race to
diagnose and treat cancer. Our high-performing tests enable
clinicians to make more confident diagnostic, prognostic, and
treatment decisions for some of the most challenging diseases such
as thyroid, prostate, breast, bladder and lung cancers, as well as
interstitial lung diseases. We help patients avoid unnecessary
procedures and speed time to diagnosis and appropriate treatment.
In addition to making our tests available in the U.S. through our
central laboratories, we also aim to deliver our tests to patients
worldwide through a distributed model to laboratories that can
perform them locally. Veracyte is based in South San Francisco,
California. For more information, please visit www.veracyte.com and
follow the company on Twitter (@veracyte).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to our statements related to our plans,
objectives, expectations (financial and otherwise) or intentions
with respect to our clinical tests in and outside of the United
States. Forward-looking statements can be identified by words such
as: “appears,” "anticipate," "intend," "plan," "expect," "believe,"
"should," "may," "will," “positioned,” “designed” and similar
references to future periods. Examples of forward-looking
statements include, among others, that Dr. Febbo will help advance
novel tests that address important unmet patient-care needs in
cancer. Additional factors that may impact these forward-looking
statements can be found under the caption “Risk Factors” in our
Annual Report on Form 10-K filed on March 1, 2023, and our
Quarterly Report on Form 10-Q filed for the three months ended June
30, 2023. Copies of these documents, when available, may be found
in the Investors section of our website at
https://investor.veracyte.com. These forward-looking statements
speak only as of the date hereof and, except as required by law, we
specifically disclaim any obligation to update these
forward-looking statements or reasons why actual results might
differ, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230927846710/en/
Investors: investors@veracyte.com 619-393-1545
Media: Tracy Morris VP of Global Corporate Communications
tracy.morris@veracyte.com 650-380-4413
Veracyte (NASDAQ:VCYT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Veracyte (NASDAQ:VCYT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024